Arizona Tribune - American Gene Technologies to Present at the NIBA 153rd Investment Conference in Fort Lauderdale

NYSE - LSE

BCC	0.68%	75.21	$
RYCEF	1.52%	19.7	$
RBGPF	0%	65	$
GSK	-0.21%	47.08	$
CMSC	0.54%	20.27	$
NGG	1.26%	76.295	$
BTI	0.48%	52.605	$
RIO	1.23%	94.03	$
AZN	-0.35%	157.15	$
BCE	-0.5%	19.82	$
JRI	0.46%	10.82	$
VOD	2.62%	16.82	$
CMSD	0.29%	20.4	$
RELX	-0.39%	33.36	$
BP	0.75%	44.835	$

American Gene Technologies to Present at the NIBA 153rd Investment Conference in Fort Lauderdale

TECHNOLOGY 02.10.2026

ROCKVILLE, MD / ACCESS Newswire / October 2, 2026 / American Gene Technologies ("AGT"), a clinical-stage biotech developing AGT103-T - the only program to demonstrate elimination of the HIV viral reservoir in humans - will present at the National Investment Banking Association (NIBA) 153rd Investment Conference on October 6-7, 2026.

Text size:

AGT is raising $55 million to fund its Phase 2 trial of this one-time, gene-modified T-cell therapy targeting a functional cure for HIV in a $40 billion annual market. Backed by a successful Phase 1 trial, FDA Fast Track designation, 60+ patents.

AGT will be available for one-on-one investor meetings on October 7. To schedule a meeting, contact Drew Palin, President, at [email protected] or visit nibanet.org for details.

SOURCE: American Gene Technologies

View the original press release on ACCESS Newswire

L.Adams--AT

Featured

Not-so-brave new world: virtual taekwondo makes Asian Games debut

Four-member crew docks at International Space Station

MicroVision Updates Start Time for Video Session & Business Update on October 7, 2026

AI Search Engineers Announces Three Q4 AI and Media Award Program Recipients as Custom AI-Optimized Websites, Schema Markup, Press Releases, and Feature Articles Deploy Oct. 1